HC Wainwright Reaffirms Buy Rating for BioLineRx (NASDAQ:BLRX)

HC Wainwright reiterated their buy rating on shares of BioLineRx (NASDAQ:BLRX) in a report issued on Tuesday morning, Benzinga reports. HC Wainwright currently has a $21.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for BioLineRx’s Q1 2024 earnings at ($0.29) EPS, Q2 2024 earnings at ($0.29) EPS, Q3 2024 earnings at ($0.24) EPS and Q4 2024 earnings at ($0.22) EPS.

Separately, StockNews.com raised BioLineRx to a sell rating in a report on Monday, December 4th.

BioLineRx Stock Up 0.9 %

BioLineRx stock opened at $1.12 on Tuesday. The firm has a market cap of $81.13 million, a price-to-earnings ratio of -1.24 and a beta of 1.40. The firm has a fifty day moving average price of $1.20 and a two-hundred day moving average price of $1.46. BioLineRx has a fifty-two week low of $0.81 and a fifty-two week high of $2.53. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.96 and a quick ratio of 1.86.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings results on Tuesday, March 26th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. The company had revenue of $4.80 million during the quarter, compared to the consensus estimate of $0.17 million. During the same period last year, the company earned ($0.09) earnings per share. As a group, analysts forecast that BioLineRx will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On BioLineRx

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. NorthRock Partners LLC acquired a new position in BioLineRx during the fourth quarter valued at approximately $27,000. B. Riley Wealth Advisors Inc. increased its position in shares of BioLineRx by 88.5% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 10,000 shares in the last quarter. Allen Mooney & Barnes Investment Advisors LLC acquired a new stake in BioLineRx during the 3rd quarter worth $46,000. Renaissance Technologies LLC raised its holdings in BioLineRx by 49.1% during the 3rd quarter. Renaissance Technologies LLC now owns 68,222 shares of the biotechnology company’s stock worth $63,000 after buying an additional 22,478 shares during the period. Finally, LPL Financial LLC boosted its holdings in shares of BioLineRx by 152.7% in the fourth quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 71,134 shares during the period. Institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.